Long-term management of pediatric psoriasis with ixekizumab: a case report

J Dermatolog Treat. 2023 Dec;34(1):2198622. doi: 10.1080/09546634.2023.2198622.

Abstract

Psoriasis in pediatric patients is uncommon and the management of moderate-to-severe cases can be challenging. We report the case of a 17-year-old girl who presented with severe plaque psoriasis unresponsive to UVB phototherapy. The Psoriasis Area Severity Index (PASI) was 18 and the Dermatology Life Quality Index was 24. We decided to prescribe ixekizumab, observing complete skin clearance after only 8 weeks. The patient is still on treatment with no reported adverse events after two years.

Keywords: Ixekizumab; pediatric; psoriasis; real-life.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Child
  • Female
  • Humans
  • Psoriasis* / therapy
  • Severity of Illness Index
  • Skin
  • Treatment Outcome
  • Ultraviolet Therapy*

Substances

  • ixekizumab
  • Antibodies, Monoclonal, Humanized